Skip to main content
Top
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Recurrence and mortality according to Estrogen Receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast

Authors: Romano Demicheli, Ilaria Ardoino, Patrizia Boracchi, Danila Coradini, Roberto Agresti, Cristina Ferraris, Massimiliano Gennaro, William JM Hrushesky, Elia Biganzoli

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

the study was designed to determine how tumour hormone receptor status affects the subsequent pattern over time (dynamics) of breast cancer recurrence and death following conservative primary breast cancer resection.

Methods

Time span from primary resection until both first recurrence and death were considered among 2825 patients undergoing conservative surgery with or without breast radiotherapy. The hazard rates for ipsilateral breast tumour recurrence (IBTR), distant metastasis (DM) and mortality throughout 10 years of follow-up were assessed.

Results

DM dynamics displays the same bimodal pattern (first early peak at about 24 months, second late peak at the sixth-seventh year) for both estrogen receptor (ER) positive (P) and negative (N) tumours and for all local treatments and metastatic sites. The hazard rates for IBTR maintain the bimodal pattern for ERP and ERN tumours; however, each IBTR recurrence peak for ERP tumours is delayed in comparison to the corresponding timing of recurrence peaks for ERN tumours. Mortality dynamics is markedly different for ERP and ERN tumours with more early deaths among patients with ERN than among patients with ERP primary tumours.

Conclusion

DM dynamics is not influenced by the extent of conservative primary tumour resection and is similar for both ER phenotypes across different metastatic sites, suggesting similar mechanisms for tumour development at distant sites despite apparently different microenvironments. The IBTR risk peak delay observed in ERP tumours is an exception to the common recurrence risk rhythm. This suggests that the microenvironment within the residual breast tissue may enforce more stringent constraints upon ERP breast tumour cell growth than other tissues, prolonging the latency of IBTR. This local environment is, however, apparently less constraining to ERN cells, as IBTR dynamics is similar to the corresponding recurrence dynamics among other distant tissues.
Appendix
Available only for authorised users
Literature
1.
go back to reference Demicheli R, Ardoino I, Biganzoli E, Boracchi P, Coradini D, Greco M, Moliterni A, Zambetti M, Valagussa P, Gukas ID, Bonadonna G: Recurrence and mortality for breast cancer patients undergoing mastectomy according to Estrogen Receptor status: different mortality pattern but comparable recurrence dynamics. Cancer Sci. 2010, 101: 826-830. 10.1111/j.1349-7006.2009.01472.x.CrossRefPubMed Demicheli R, Ardoino I, Biganzoli E, Boracchi P, Coradini D, Greco M, Moliterni A, Zambetti M, Valagussa P, Gukas ID, Bonadonna G: Recurrence and mortality for breast cancer patients undergoing mastectomy according to Estrogen Receptor status: different mortality pattern but comparable recurrence dynamics. Cancer Sci. 2010, 101: 826-830. 10.1111/j.1349-7006.2009.01472.x.CrossRefPubMed
2.
go back to reference Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM: Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998, 52: 227-237. 10.1023/A:1006133418245.CrossRefPubMed Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM: Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998, 52: 227-237. 10.1023/A:1006133418245.CrossRefPubMed
3.
go back to reference Dignam JJ, Dukic V, Anderson SJ, Mamounas EP, Wickerham DL, Wolmark N: Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat. 2009, 116: 595-602. 10.1007/s10549-008-0200-5.CrossRefPubMed Dignam JJ, Dukic V, Anderson SJ, Mamounas EP, Wickerham DL, Wolmark N: Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat. 2009, 116: 595-602. 10.1007/s10549-008-0200-5.CrossRefPubMed
4.
go back to reference Demicheli R, Biganzoli E, Boracchi P, Greco M, Retsky MW: Recurrence dynamics does not depend on the recurrence site. Breast Cancer Res. 2008, 10: R83-10.1186/bcr2152.CrossRefPubMedPubMedCentral Demicheli R, Biganzoli E, Boracchi P, Greco M, Retsky MW: Recurrence dynamics does not depend on the recurrence site. Breast Cancer Res. 2008, 10: R83-10.1186/bcr2152.CrossRefPubMedPubMedCentral
5.
go back to reference Hess KR, Pustzai L, Buzdar AU, Hortobagyi GN: Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat. 2003, 78: 105-118. 10.1023/A:1022166517963.CrossRefPubMed Hess KR, Pustzai L, Buzdar AU, Hortobagyi GN: Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat. 2003, 78: 105-118. 10.1023/A:1022166517963.CrossRefPubMed
6.
go back to reference Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G: Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat. 2000, 59: 271-278. 10.1023/A:1006308619659.CrossRefPubMed Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G: Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat. 2000, 59: 271-278. 10.1023/A:1006308619659.CrossRefPubMed
7.
go back to reference Howell A, Barnes DM, Harland RN, Redford J, Bramwell VH, Wilkinson MJ, Swindell R, Crowther D, Sellwood RA: Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet. 1984, 1: 588-5891. 10.1016/S0140-6736(84)90995-4.CrossRefPubMed Howell A, Barnes DM, Harland RN, Redford J, Bramwell VH, Wilkinson MJ, Swindell R, Crowther D, Sellwood RA: Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet. 1984, 1: 588-5891. 10.1016/S0140-6736(84)90995-4.CrossRefPubMed
8.
go back to reference Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of randomised trials. Lancet. 1998, 351: 1451-1467. 10.1016/S0140-6736(97)11423-4.CrossRef Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of randomised trials. Lancet. 1998, 351: 1451-1467. 10.1016/S0140-6736(97)11423-4.CrossRef
9.
go back to reference Anderson WF, Matsuno R: Breast cancer heterogeneity: a mixture of at least two main types?. J Natl Cancer Inst. 2006, 98: 948-951. 10.1093/jnci/djj295.CrossRefPubMed Anderson WF, Matsuno R: Breast cancer heterogeneity: a mixture of at least two main types?. J Natl Cancer Inst. 2006, 98: 948-951. 10.1093/jnci/djj295.CrossRefPubMed
10.
go back to reference Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, Borresen-Dale AL: Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 2006, 7: 127-10.1186/1471-2164-7-127.CrossRefPubMedPubMedCentral Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, Borresen-Dale AL: Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 2006, 7: 127-10.1186/1471-2164-7-127.CrossRefPubMedPubMedCentral
11.
go back to reference Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, Peterson C, Meltzer S: Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 2001, 61: 5979-5984.PubMed Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, Peterson C, Meltzer S: Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 2001, 61: 5979-5984.PubMed
12.
go back to reference Veronesi U, Saccozzi R, Del Vecchio M, Banfi A, Clemente C, De Lena M, Gallus G, Greco M, Luini A, Marubini E, Muscolino G, Rilke F, Salvadori B, Zecchini A, Zucali R: Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med. 1981, 305: 6-11. 10.1056/NEJM198107023050102.CrossRefPubMed Veronesi U, Saccozzi R, Del Vecchio M, Banfi A, Clemente C, De Lena M, Gallus G, Greco M, Luini A, Marubini E, Muscolino G, Rilke F, Salvadori B, Zecchini A, Zucali R: Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med. 1981, 305: 6-11. 10.1056/NEJM198107023050102.CrossRefPubMed
13.
go back to reference Veronesi U, Volterrani F, Luini A, Saccozzi R, Del Vecchio M, Zucali R, Galimberti V, Rasponi A, Di Re E, Squicciarini P: Quadrantectomy versus lumpectomy for small size breast cancer. Eur J Cancer. 1990, 26: 671-673. 10.1016/0277-5379(90)90114-9.CrossRefPubMed Veronesi U, Volterrani F, Luini A, Saccozzi R, Del Vecchio M, Zucali R, Galimberti V, Rasponi A, Di Re E, Squicciarini P: Quadrantectomy versus lumpectomy for small size breast cancer. Eur J Cancer. 1990, 26: 671-673. 10.1016/0277-5379(90)90114-9.CrossRefPubMed
14.
go back to reference Veronesi U, Luini A, Del Vecchio M, Greco M, Galimberti V, Merson M, Rilke F, Sacchini V, Saccozzi R, Savio T: Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med. 1993, 328: 1587-1591. 10.1056/NEJM199306033282202.CrossRefPubMed Veronesi U, Luini A, Del Vecchio M, Greco M, Galimberti V, Merson M, Rilke F, Sacchini V, Saccozzi R, Savio T: Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med. 1993, 328: 1587-1591. 10.1056/NEJM199306033282202.CrossRefPubMed
15.
go back to reference Marubini E, Mariani L, Salvadori B, Veronesi U, Saccozzi R, Merson M, Zucali R, Rilke F: Results of a breast-cancer-surgery trial compared with observational data from routine practice. Lancet. 1996, 347: 1000-1003. 10.1016/S0140-6736(96)90145-2.CrossRefPubMed Marubini E, Mariani L, Salvadori B, Veronesi U, Saccozzi R, Merson M, Zucali R, Rilke F: Results of a breast-cancer-surgery trial compared with observational data from routine practice. Lancet. 1996, 347: 1000-1003. 10.1016/S0140-6736(96)90145-2.CrossRefPubMed
16.
go back to reference Demicheli R, Retsky MW, Hrushesky WJM, Baum M: Tumor dormancy and surgery-driven dormancy interruption in breast cancer: learning from failures. Nature Clin Pract Oncol. 2007, 4: 699-710. 10.1038/ncponc0999.CrossRef Demicheli R, Retsky MW, Hrushesky WJM, Baum M: Tumor dormancy and surgery-driven dormancy interruption in breast cancer: learning from failures. Nature Clin Pract Oncol. 2007, 4: 699-710. 10.1038/ncponc0999.CrossRef
17.
go back to reference Rosen PP, Fracchia AA, Urban JA, Schottenfeld D, Robbins GF: "Residual" mammary carcinoma following simulated partial mastectomy. Cancer. 1975, 35: 739-747. 10.1002/1097-0142(197503)35:3<739::AID-CNCR2820350329>3.0.CO;2-5.CrossRefPubMed Rosen PP, Fracchia AA, Urban JA, Schottenfeld D, Robbins GF: "Residual" mammary carcinoma following simulated partial mastectomy. Cancer. 1975, 35: 739-747. 10.1002/1097-0142(197503)35:3<739::AID-CNCR2820350329>3.0.CO;2-5.CrossRefPubMed
18.
go back to reference Vaidya JS, Vyas JJ, Chinoy RF, Merchant N, Sharma OP, Mittra I: Multicentricity of breast cancer: whole-organ analysis and clinical implications. Br J Cancer. 1996, 74: 820-824.CrossRefPubMedPubMedCentral Vaidya JS, Vyas JJ, Chinoy RF, Merchant N, Sharma OP, Mittra I: Multicentricity of breast cancer: whole-organ analysis and clinical implications. Br J Cancer. 1996, 74: 820-824.CrossRefPubMedPubMedCentral
19.
go back to reference Santen RJ, Santner SJ, Pauley RJ, Tait L, Kaseta J, Demers LM, Hamilton C, Yue W, Wang JP: Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible?. J Steroid Biochem Mol Biol. 1997, 61: 267-271. 10.1016/S0960-0760(97)80022-2.CrossRefPubMed Santen RJ, Santner SJ, Pauley RJ, Tait L, Kaseta J, Demers LM, Hamilton C, Yue W, Wang JP: Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible?. J Steroid Biochem Mol Biol. 1997, 61: 267-271. 10.1016/S0960-0760(97)80022-2.CrossRefPubMed
20.
go back to reference Haveman J, Rodermond H, vanBree C, Wondergem J, Franken NAP: Residual late radiation damage in mouse stromal tissue assessed by tumor bed effect. J Radiat Res. 2007, 48: 107-112. 10.1269/jrr.0631.CrossRefPubMed Haveman J, Rodermond H, vanBree C, Wondergem J, Franken NAP: Residual late radiation damage in mouse stromal tissue assessed by tumor bed effect. J Radiat Res. 2007, 48: 107-112. 10.1269/jrr.0631.CrossRefPubMed
21.
go back to reference Shao C, Folkard M, Held KD, Prise KM: Estrogen enhanced cell-cell signalling in breast cancer cells exposed to targeted irradiation. BMC Cancer. 2008, 8: 184-10.1186/1471-2407-8-184.CrossRefPubMedPubMedCentral Shao C, Folkard M, Held KD, Prise KM: Estrogen enhanced cell-cell signalling in breast cancer cells exposed to targeted irradiation. BMC Cancer. 2008, 8: 184-10.1186/1471-2407-8-184.CrossRefPubMedPubMedCentral
22.
go back to reference Gupta GP, Massaguè G: Cancer metastasis: building a framework. Cell. 2006, 127: 679-695. 10.1016/j.cell.2006.11.001.CrossRefPubMed Gupta GP, Massaguè G: Cancer metastasis: building a framework. Cell. 2006, 127: 679-695. 10.1016/j.cell.2006.11.001.CrossRefPubMed
23.
go back to reference Paget S: The distribution of secondary growth in cancer of the breast. Lancet. 1889, 1: 571-573. 10.1016/S0140-6736(00)49915-0.CrossRef Paget S: The distribution of secondary growth in cancer of the breast. Lancet. 1889, 1: 571-573. 10.1016/S0140-6736(00)49915-0.CrossRef
24.
go back to reference Hodges GM, Hicks RM, Spacey GD: Epithelial-stromal interactions in normal and chemical-carcinogen treated adult bladder. Cancer Res. 1977, 37: 3720-3730.PubMed Hodges GM, Hicks RM, Spacey GD: Epithelial-stromal interactions in normal and chemical-carcinogen treated adult bladder. Cancer Res. 1977, 37: 3720-3730.PubMed
25.
go back to reference Barcellos-Hoff MH, Ravani SA: Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 2000, 60: 1254-1260.PubMed Barcellos-Hoff MH, Ravani SA: Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 2000, 60: 1254-1260.PubMed
26.
go back to reference Maffini MV, Soto AM, Calabro JM, Ucci AA, Sonnenschein C: The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci. 2004, 117: 1495-502. 10.1242/jcs.01000.CrossRefPubMed Maffini MV, Soto AM, Calabro JM, Ucci AA, Sonnenschein C: The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci. 2004, 117: 1495-502. 10.1242/jcs.01000.CrossRefPubMed
27.
go back to reference Decosse JJ, Glossens CL, Kluzma JF, Unsworth D: Breast cancer: induction of differentiation by embryonic tissue. Science. 1973, 181: 1057-1058. 10.1126/science.181.4104.1057.CrossRefPubMed Decosse JJ, Glossens CL, Kluzma JF, Unsworth D: Breast cancer: induction of differentiation by embryonic tissue. Science. 1973, 181: 1057-1058. 10.1126/science.181.4104.1057.CrossRefPubMed
28.
go back to reference Fukamachi HA, Mizuno T, Kim JS: Gland formation of human colon cancer cells combined with foetal rat mesenchyme in organ culture: an ultrasctuctural study. J Cell Sci. 1987, 87: 615-621.PubMed Fukamachi HA, Mizuno T, Kim JS: Gland formation of human colon cancer cells combined with foetal rat mesenchyme in organ culture: an ultrasctuctural study. J Cell Sci. 1987, 87: 615-621.PubMed
29.
go back to reference Dotto GP, Weinberg RA, Ariza A: Malignant transformation of mouse primary keratinocytes by Harvey sarcoma virus and its modulation by surrounding normal cells. Proc Natl Acad Sci USA. 1988, 85: 6389-6393. 10.1073/pnas.85.17.6389.CrossRefPubMedPubMedCentral Dotto GP, Weinberg RA, Ariza A: Malignant transformation of mouse primary keratinocytes by Harvey sarcoma virus and its modulation by surrounding normal cells. Proc Natl Acad Sci USA. 1988, 85: 6389-6393. 10.1073/pnas.85.17.6389.CrossRefPubMedPubMedCentral
30.
go back to reference Hayashi N, Cunha GR: Mesenchyme-induced changes in neoplastic characteristics of the Dunning prostatic adenocarcinoma. Cancer Res. 1991, 51: 4924-4930.PubMed Hayashi N, Cunha GR: Mesenchyme-induced changes in neoplastic characteristics of the Dunning prostatic adenocarcinoma. Cancer Res. 1991, 51: 4924-4930.PubMed
31.
go back to reference Kuperwasser C: Reconstruction of functionally normal and malignant breast tissues in mice. Proc Natl Acad Sci USA. 2004, 101: 4966-4971. 10.1073/pnas.0401064101.CrossRefPubMedPubMedCentral Kuperwasser C: Reconstruction of functionally normal and malignant breast tissues in mice. Proc Natl Acad Sci USA. 2004, 101: 4966-4971. 10.1073/pnas.0401064101.CrossRefPubMedPubMedCentral
32.
go back to reference Brinster RL: The effect of cells transferred into the mouse blastocyst on subsequent development. J Exp Med. 1974, 140: 1049-1056. 10.1084/jem.140.4.1049.CrossRefPubMedPubMedCentral Brinster RL: The effect of cells transferred into the mouse blastocyst on subsequent development. J Exp Med. 1974, 140: 1049-1056. 10.1084/jem.140.4.1049.CrossRefPubMedPubMedCentral
33.
go back to reference Mintz B, Illmensee K: Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc Natl Acad Sci USA. 1975, 72: 3585-3589. 10.1073/pnas.72.9.3585.CrossRefPubMedPubMedCentral Mintz B, Illmensee K: Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc Natl Acad Sci USA. 1975, 72: 3585-3589. 10.1073/pnas.72.9.3585.CrossRefPubMedPubMedCentral
34.
go back to reference Shekhar MP, Werdell J, Santner SJ, Pauley RJ, Tait R: Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumour development and progression. Cancer Res. 2001, 61: 1320-1326.PubMed Shekhar MP, Werdell J, Santner SJ, Pauley RJ, Tait R: Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumour development and progression. Cancer Res. 2001, 61: 1320-1326.PubMed
35.
go back to reference Fisher B: Laboratory and clinical research in breast cancer: a personal adventure: the David A. Karnofsky memorial lecture. Cancer Res. 1980, 40: 3863-74.PubMed Fisher B: Laboratory and clinical research in breast cancer: a personal adventure: the David A. Karnofsky memorial lecture. Cancer Res. 1980, 40: 3863-74.PubMed
Metadata
Title
Recurrence and mortality according to Estrogen Receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast
Authors
Romano Demicheli
Ilaria Ardoino
Patrizia Boracchi
Danila Coradini
Roberto Agresti
Cristina Ferraris
Massimiliano Gennaro
William JM Hrushesky
Elia Biganzoli
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-656

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine